Elena Sevillano M.D. PhD
@elenasefer
Followers
453
Following
1K
Media
23
Statuses
227
Joined March 2011
🚀 Only 1 month left! Join us for Innovation in Urothelial Cancer 2025 on Dec 11 with leading experts in the field. 🔥 Cutting-edge topics: MIBC transformation, bladder-sparing breakthroughs, ctDNA-guided personalization, mUC sequencing & precision oncology. Don’t miss it!
1
1
2
¡CANVES arranca la nueva temporada de GUSpot! Junto al Dr. @Álvaro Pinto hablamos del origen de CANVES y del valor de dar voz y apoyo a pacientes y cuidadores. Mira el capítulo completo ( https://t.co/X1KFSkrDtd)
1
4
15
🚨 Hot off the press! New Spanish SEOM–SOGUG 2025 guidelines on bladder cancer Highlights: ✔️ Periop durva ✔️ EV+pembro 1L mUC ✔️ Updated NMIBC–MIBC–mUC More changes on the horizon, another update will be needed soon! https://t.co/5HxGoH2eCF
@_SEOM @sogug1 @docjavip @begopval
0
4
4
🔴 #EnDirecto_iSanidad| @JNJInnovMedES anuncia la llegada a España de erdafitinib (Balversa), el primer y único tratamiento oral aprobado en la Unión Europea para pacientes con carcinoma urotelial avanzado (irresecable o metastásico) con alteraciones del FGFR3 tras al menos una
0
3
4
✅#Balversa, disponible en España para pacientes con carcinoma urotelial avanzado con alteraciones del FGFR3 🗣️Según Jacobo Muñoz, director médico de @JNJNews, este tratamiento "marca la entrada de la compañía en el campo de la medicina de precisión" https://t.co/bfq4abJuBs
elglobalfarma.com
Según Jacobo Muñoz, el tratamiento Balversa "marca la entrada de la compañía Johnson & Johnson en el campo de la medicina de precisión"
0
4
8
SASAN-SPARING trial: Bladder-sparing approach for muscle-invasive #BladderCancer. @elenasefer joins @zklaassen_md @GACancerCenter to discuss alternatives to radical cystectomy given its significant impact on patients' urinary, bowel, and sexual function, noting that some patients
1
2
13
Proud of my co-worker @elenasefer, hard work pays off 👏
🎉 Proud to present our SASAN-SPARING phase 2 trial poster today at #ASCO25! A novel bladder-sparing strategy using sasanlimab as maintenance after neoadjuvant chemo in MIBC. Integrating ctDNA, utDNA, and multi-omic biomarkers to personalize treatment and save bladders
0
2
7
Happy to be co-lead the SASAN-SPARING phase 2 trial with @elenasefer presented at #ASCO25! A bladder-sparing approach using sasanlimab post-neoadjuvant cisplatin in MIBC. First 16 patients enrolled — stay tuned, results coming soon! #BladderCancer #Immunotherapy
🎉 Proud to present our SASAN-SPARING phase 2 trial poster today at #ASCO25! A novel bladder-sparing strategy using sasanlimab as maintenance after neoadjuvant chemo in MIBC. Integrating ctDNA, utDNA, and multi-omic biomarkers to personalize treatment and save bladders
1
2
14
Congratulations @elenasefer @g_develasco et al. for this really elegant trial! Looking forward to more data :-)
🎉 Proud to present our SASAN-SPARING phase 2 trial poster today at #ASCO25! A novel bladder-sparing strategy using sasanlimab as maintenance after neoadjuvant chemo in MIBC. Integrating ctDNA, utDNA, and multi-omic biomarkers to personalize treatment and save bladders
0
3
11
Trials-in-progress – sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with MIBC: The phase 2, SASAN-SPARING trial. Presentation by @elenasefer. #ASCO25 written coverage by @RKSayyid > https://t.co/wOQApzyBCz
0
3
9
@elenasefer @g_develasco @Juanfran_jf @jgarciadonas @DrFelixGuerrero @ArantzazuBarqu1 Congratulations on making this investigator-initiated study a reality! A well-designed trial with strong translational science. Looking forward to the insights it will bring. Most importantly, it offers hope for patients seeking a bladder-sparing approach. Well done!
0
2
5
🎉 Proud to present our SASAN-SPARING phase 2 trial poster today at #ASCO25! A novel bladder-sparing strategy using sasanlimab as maintenance after neoadjuvant chemo in MIBC. Integrating ctDNA, utDNA, and multi-omic biomarkers to personalize treatment and save bladders
3
13
50
Un honor haber organizado la 6ª Reunión Anual de Carcinoma Urotelial, con la participación de grandes especialistas. Gracias a ponentes, colaboradores y asistentes por su valiosa presencia. #Urotelial #Oncología #CursoAnualdeUC #Colaboración #FormaciónMédica
2
9
34
Parece que en esto hay consenso: 🗣 ¿Es posible la curación en cáncer urotelial metastásico? 💬 Con base en los datos EV-103 y EV-302, los 4 ponentes coinciden. #BladderCancer #GUTrends25
@tompowles1 @nachoduranm @elenasefer @DrIacovelli
@Uromigos @OncoAlert @OncobitesTv
0
10
11
Day One #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 https://t.co/VFmzMWtIHf
@elenasefer 🇪🇸 of @GuardConsortium Covering Landcape changing Trials in #KidneyCancer REGISTER NOW for a Live chat with Dr. Sevillano In 2024, key kidney cancer trials brought significant
0
9
18
Day One #OncoAlertColloquium 🚨STARTS TODAY 12 noon EST🇺🇸 6PM CET🇪🇺 REGISTER for FREE HERE👉 https://t.co/JZzXNUHXyu To Accèss the Videos and the LIVE chat with the Experts, you will need a link and password which will be provided upon registration. Todays Schedule: (we
1
14
22
El Mentorship Research Group de @GuardConsortium lanza el Programa de Mentorización para jóvenes investigadores. Es tu oportunidad para desarrollar un proyecto de investigación dentro de @GuardConsortium, ¡te esperamos! Más información aquí: https://t.co/2ASQXAAeY3
0
4
9
Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. https://t.co/8oRNdVgwZd
4
83
183